CAR-T Referral Process: Insights from UCSF : Episode 3
Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?
Panelists discuss how, for second-line treatment of relapsed/refractory multiple myeloma (R/R MM), patients suitable for CAR T-cell (cilta-cel vs ide-cel) therapy typically have a poor prognosis with limited response to prior therapies. Institutional guidelines focus on factors such as prior lines of therapy, organ function, and cytogenetics. Non-medical factors, such as geographic access and financial constraints, also influence CAR T-cell therapy referral eligibility.
EP: 1.Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma
EP: 2.Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment
Now Viewing
EP: 3.Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?
EP: 4.Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection
EP: 5.CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy
EP: 6.Care Coordination and Transition Strategies for CAR -T Therapy
EP: 7.CAR -T Therapy in Early Lines of R/R MM: Clinical Scenario Discussion and Key Takeaways
EP: 8.Key Takeaways in CAR-T Therapy for Multiple Myeloma
Video content above is prompted by the following:
- Which patients do you consider for CAR T-cell therapy in second-line treatment for R/R MM (cilta-cel vs ide-cel)?
- Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR T-cell therapy referral?
- How do nonmedical factors (location, money, etc) impact patient selection?
Recent Videos
Related Content
